
US Tariffs Hit Indian Pharma Stocks Hard
The Nifty Pharma Index opened lower at 21,672.85 on Tuesday, marking a significant dip from Monday's close. By the morning, it fell to 21,359.30, a drop of nearly 2%. This decline is linked to news that U.S. President Donald Trump plans to impose tariffs on pharmaceutical imports soon. The tariffs aim to boost domestic drug manufacturing in the U.S., which has caused Indian pharmaceutical companies' share prices, like Lupin and Cipla, to correct sharply by 2-3%. Investors are advised to consult experts before making investment decisions as the market reacts to these developments.